Key Highlights

  • Third-quarter 2026 Revenue was USD 3.6 million, against USD 3.5 million a year earlier.
  • Net loss was USD 7.3 million, or USD 0.15 per share.
  • Cash and cash equivalents were USD 21.8 million at September 30, 2026.
  • The company closed 34 new accounts and launched AI Highlights in the U.S.

CapsoVision (NASDAQ:CV) reported third-quarter 2026 revenue of USD 3.6 million, against an estimate of USD 3.74 million. Net loss per share was USD 0.15, in line with an estimate of a loss of USD 0.15. The company makes the CapsoCam Plus capsule endoscopy system used for small bowel screening.

Management said the quarter reflected a competitive pricing environment in the U.S. for small bowel capsule endoscopy, even as the company continued to expand its customer base. It said it plans to submit its second-generation colon platform to the FDA before year-end 2026.

Commercial Performance

The company shipped 8,464 CapsoCam Plus capsules in the third quarter, against 8,336 in the third quarter of 2025. Management said CapsoCam Plus for small bowel screening has been used by more than 184,000 patients as of September 30, 2026, against 151,000 a year earlier, across the U.S. and internationally.

It said it closed 34 new accounts, including 9 hospital systems, 4 pediatric hospital clinics and 21 adult GI clinics, and named Carilion Health Systems, Methodist Hospital Systems and additional locations within Gastro Health and Kaiser Permanente among the additions. Management described the current customer mix as roughly 65% GI clinics and 35% hospital systems and said its technology is protected by 85 issued U.S. patents.

AI Highlights for small bowel launched in the U.S. on November 2. Management said it gives the sales team a way to demonstrate reading efficiency, accuracy and diagnostic confidence, and that some large customers and health systems had been waiting for FDA clearance of AI Highlights before evaluating CapsoCam Plus against competing systems.

Financial Results

Third-quarter revenue was USD 3.6 million, against USD 3.5 million in the prior-year quarter, a change of 1% as stated by management, and average selling price was stable year over year. Gross Profit was USD 1.8 million, against USD 1.9 million, with a gross Margin of 49%, against 54% a year earlier.

Operating expenses were USD 9.1 million, against USD 9.9 million, which management said reflects continued expense management while supporting clinical and development programs, including the CapsoCam Colon pivotal study. Net loss was USD 7.3 million, or USD 0.15 per share, against USD 7.9 million, or USD 0.17 per share.

The filing reports USD 1,643 thousand of expenses for ongoing clinical trial activities in the quarter, against USD 2,350 thousand, and USD 5,649 thousand for the nine months, against USD 4,102 thousand. Accrued Research and Development expenses were USD 3,399 thousand at September 30, 2026, against USD 1,448 thousand at December 31, 2025.

Cash, Financing and Pipeline

The company ended September 30 with USD 21.8 million in cash and cash equivalents. The balance included net proceeds of approximately USD 17.8 million from a registered direct offering with existing shareholders that closed on September 18. It also sold 276,446 shares under its at-the-market Facility during the quarter for net proceeds of USD 1.7 million.

Management said the financing provides resources to support the AI rollout, the planned colon submission and ongoing clinical development. It estimates the initial U.S. annual addressable market for patients at high risk for colonoscopy or with an incomplete procedure at approximately USD 1 billion, and a longer-term colon opportunity above USD 10 billion.

It also said it is expanding its CapsoCam UGI study for pancreatic cancer detection, with two active community-based clinical sites and site activation advancing at more than a dozen large-volume centers. Management said the program is early stage and that data supporting the colon submission would be available next month, with a decision on public sharing still to be made.